Shots:

• The WAC cost of Mvasi and Kanjinti is 15% lower than their reference products i.e Avastin and Herceptin respectively. Mvasi is available at WAC of $677.40/100 mg and $2-709.60/400 mg single-dose vial and Kanjinti is being made available at a WAC of $3-697.26/420 mg multi-dose vial-
• During launch Mvasi and Kanjinti will be 12% and 13% respectively lower to average selling price (ASP) of their reference products. The products were proved to be highly similar to- with no clinically meaningful differences in terms of safety and effectiveness from Avastin and Herceptin respectively based on analytical- clinical safety and efficacy data
• Mvasi (bevacizumab-awwb) is an IgG1 mAb approved by the US FDA for 5 types of cancer- plus chemotherapy/interferon-alfa for mCRC- non-sq NSCLC- recurrent glioblastoma metastatic RCC and persistent- recurrent- or metastatic cervical cancer. Kanjinti (trastuzumab-anns) is a recombinant DNA-derived IgG1 kappa antibody all indications of reference product

Click here to read full press release/ article | Ref: Amgen | Image: Behance